Keywords:
Abdomen, Kidney, CT, Contrast agent-intravenous, Cancer
Authors:
Y. Ogawa, S. Morita, T. Takagi, K. Yoshida, K. Tanabe, Y. Nagashima, Y. Nishina, S. Sakai; Tokyo/JP
DOI:
10.26044/ecr2021/C-11231
Conclusion
The EDCB sign, which is an unenhanced thin line at the tumor-renal cortex border in the corticomedullary phase CT images, was observed in nearly two-thirds of ccRCCs treated by partial nephrectomy. Although the EDCB could reflect pathological pseudocapsule of ccRCC, diagnostic accuracy was inadequate. The EDCB sign can be one of the predictors for differentiating ccRCC from Fp-AML, as it was not observed in Fp-AML.
The discussion points and limitations are as follows:
- Detection of the EDCB depends on the tumor vascularity based on the tumor subtypes, resulting in observation mainly in ccRCCs. It cannot be observed on the border with the renal medulla or poorly enhanced parts of tumors.
- Oncocytoma, an early enhanced benign tumor, is difficult to differentiate from ccRCC using EDCB as this was observed in some cases.
- The number of Fp-AML was small compared to that of ccRCC, which could affect the results.
- Direct comparison with pathological findings of pseudocapsules in individual cases was not performed.
These points will be discussed in our manuscript with a larger population which is scheduled to be published in European Radiology [9].